9 stories mentioning SHE:300199Updated 3d ago
Every FINWIRES story that references SHE:300199, newest first.
Hybio Pharmaceutical (SHE:300199) said its HY3003 injection clinical trial application has been accepted by China's medical products regulator.The product is intended for long-term weight management in adults, according to a Friday filing with the Shenzhen bourse.Shares of the pharmaceutical company were down 4% in recent trade.
Hybio Pharmaceutical's (SHE:300199) unit, Gansu Chengji Biopharmaceutical, received the drug registration certificate from China's National Medical Products Administration for carboprost tromethamine injection, according to a Shenzhen bourse filing on Tuesday.The drug is used to treat postpartum hemorrhage caused by uterine atony.The pharmaceutical company's shares fell 2% during the afternoon trade.
Hybio Pharmaceutical's (SHE:300199) Pingshan Branch in China passed the U.S. Food and Drug Administration's inspection after no deficiencies requiring regulatory action were found, according to a Shenzhen bourse filing on Thursday.The routine inspection was conducted between June 18 and June 26 in compliance with current good manufacturing practice (cGMP) requirements for drug manufacturing.The Chinese pharmaceutical company's shares slipped 1% during the afternoon trade.
Hybio Pharmaceutical (SHE:300199) signed a cooperation agreement with Zhejiang Sunshine Mandi Pharmaceutical for the development and marketing of products related to semaglutide injection, according to a Shenzhen bourse filing on Thursday.Both parties will co-develop a semaglutide injection in a cartridge with an adjustable injection pen, which will cater to adult patients with type 2 diabetes mellitus.The Chinese pharmaceutical company will receive an upfront signing payment of 12 million yuan from Sunshine Mandi, then 18 million yuan upon the drug regulator's approval and 7.5 million yuan upon approval of the first commercial batch.Sunshine Mandi will be given exclusive rights to market the product in China region.Hybio completed the phase III clinical trial of semaglutide injection in China.Hybio's shares rose 2% at the close.
Hybio Pharmaceutical (SHE:300199) submitted its marketing authorization application to China's National Medical Products Administration for its tirzepatide injection, according to a Saturday filing with the Shenzhen bourse.The drug is indicated for type 2 diabetes, weight management, and sleep apnea, the company said in its filing.Shares closed 4% higher on Monday.
Hybio Pharmaceutical (SHE:300199) obtained domestic production approval from China's drug regulator for its liraglutide (H) injection.The drug is indicated for type two diabetes glycemic control, according to a Friday filing with the Shenzhen bourse.Shares of the pharmaceutical company were up 8% in recent trade.
Chinese shares were flat with a downward bias as the country's central bank kept rates steady.The Shanghai Composite Index, the main gauge of Chinese stocks, ticked down 0.2% to 4,162.18. The Shenzhen Component Index barely changed to 15,569.98 from 15,569.91.The People's Bank of China left benchmark rates unchanged in May for the 12th straight month, in line with forecasts. The one-year loan prime rate remained at 3%, while the five-year LPR stayed at 3.5%.Meanwhile, the meeting between Chinese President Xi Jinping and Russian leader Vladimir Putin could substantially raise Russia's energy exports to China. The Kremlin expects both leaders to hold "serious" and "very detailed" discussions on the long-delayed Power of Siberia 2 gas pipeline.The pipeline is set to carry 50 billion cubic meters to China from Russian gas fields that once served Europe.Also, Putin has invited Xi to visit Russia in 2027, saying that the ties between their two countries are at "an unprecedented level."In company news, Hybio Pharmaceutical (SHE:300199) signed a framework agreement for the sale of peptide active pharmaceutical ingredients with an undisclosed counterparty. Shares of the pharmaceutical company were down 2% Wednesday.
Hybio Pharmaceutical (SHE:300199) signed a framework agreement for the sale of peptide active pharmaceutical ingredients with an undisclosed counterparty.The agreement covers certain markets in the Americas, with a minimum sales value of 327 million yuan, according to a Wednesday filing with the Shenzhen bourse.Shares of the pharmaceutical company were down 1% in recent trade.
Hybio Pharmaceutical (SHE:300199) received approval from Indonesia's drug and food regulatory for the marketing of carbetocin injection, which trades as Uterocin, according to a Shenzhen bourse filing on Friday.The drug is used to reduce the risk of postpartum hemorrhage.The pharmaceutical company's shares jumped by less than 4% at the close.
